IL6 and liver cancer: On the other hand, a work recently published by Lanton et al. using a model of chronic inflammation-associated liver cancer revealed that the inhibition of interleukin 6 (IL-6) signaling impeded tumorigenesis following PH without vascular occlusion and did not affect survival or recovery of the liver mass [52].